Sanara Medtech Inc
NASDAQ:SMTI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.86
41.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sanara Medtech Inc
Sanara Medtech Inc
Revenue
Sanara Medtech Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanara Medtech Inc
NASDAQ:SMTI
|
Revenue
$78.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
56%
|
CAGR 10-Years
42%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Revenue
$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Revenue
$2.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Revenue
$4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Revenue
$1.5B
|
CAGR 3-Years
57%
|
CAGR 5-Years
34%
|
CAGR 10-Years
18%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Revenue
$1.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Sanara Medtech Inc
Revenue Breakdown
Breakdown by Geography
Sanara Medtech Inc
Breakdown by Segments
Sanara Medtech Inc
|
Total Revenue:
65m
USD
|
|
Soft Tissue Repair Products:
54.8m
USD
|
|
Bone Fusion Products:
10m
USD
|
|
Royalty:
201k
USD
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
What is Sanara Medtech Inc's Revenue?
Revenue
78.1m
USD
Based on the financial report for Sep 30, 2024, Sanara Medtech Inc's Revenue amounts to 78.1m USD.
What is Sanara Medtech Inc's Revenue growth rate?
Revenue CAGR 10Y
42%
Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Sanara Medtech Inc have been 53% over the past three years , 56% over the past five years , and 42% over the past ten years .
You don't have any saved screeners yet
